Semaglutide receives positive 16-0 vote in favour of approval from FDA Advisory Committee
(WorldNews Denmark)

Semaglutide receives positive 16-0 vote in favour of approval from FDA Advisory Committee Bagsværd, Denmark, 18 October 2017 - Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0 in favour of the approval of once-weekly semaglutide to improve glycaemic control in adults with type 2 diabetes. One member of the committee abstained. Based on the data included in the New Drug Application (NDA) for semaglutide, the FDA asked the panel members to discuss whether Novo Nordisk has provided adequate evidence to establish the efficacy and...